Home › Funds › SUPERSTRING CAPITAL MANAGEMENT LP › XENE
SUPERSTRING CAPITAL MANAGEMENT LP position in XENE
XENON PHARMACEUTICALS INC · Health Care
SUPERSTRING CAPITAL MANAGEMENT LP reported holding 26,496 shares of XENE (XENON PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$985K, representing 0.49% of its reported portfolio and ranking #31 among its reported holdings. SUPERSTRING CAPITAL MANAGEMENT LP first reported this position in Q3 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How SUPERSTRING CAPITAL MANAGEMENT LP's XENE position evolved
SUPERSTRING CAPITAL MANAGEMENT LP first disclosed a stake in XENE in Q3 2026 at 26,496 shares (US$985K).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2026 | 26.50K | $985.39K | New |
About XENE and 13F data
XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in XENE — the largest reported positions include Avoro Capital Advisors LLC (US$204.5M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$132.3M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$97.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding XENE
- Avoro Capital Advisors LLC 5.50M sh · $204.54M · Q3 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 3.56M sh · $132.31M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.62M sh · $97.52M · Q2 2026
- Affinity Asset Advisors, LLC 1.90M sh · $70.67M · Q3 2026
- BRAIDWELL LP 1.13M sh · $68.29M · Q2 2026
- ORBIMED ADVISORS LLC 892.47K sh · $53.87M · Q2 2026
- Caligan Partners LP 889.94K sh · $53.72M · Q2 2026
- Vestal Point Capital, LP 700.00K sh · $42.25M · Q2 2026
More on SUPERSTRING CAPITAL MANAGEMENT LP
FAQ
How long has SUPERSTRING CAPITAL MANAGEMENT LP held XENE?
SUPERSTRING CAPITAL MANAGEMENT LP has disclosed XENE holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is SUPERSTRING CAPITAL MANAGEMENT LP's current position in XENE?
As of Q3 2026, SUPERSTRING CAPITAL MANAGEMENT LP holds 26.50K shares of XENE (XENON PHARMACEUTICALS INC), valued at $985.39K, representing 0.49% of its reported portfolio and ranking #31.
Has SUPERSTRING CAPITAL MANAGEMENT LP been buying or selling XENE?
In the latest 13F filing (Q3 2026), SUPERSTRING CAPITAL MANAGEMENT LP newly opened its position in XENE.
Which other funds hold XENE?
Other major institutional holders of XENE include Avoro Capital Advisors LLC, DRIEHAUS CAPITAL MANAGEMENT LLC, DEERFIELD MANAGEMENT COMPANY, L.P., among 32 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.